Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS

Next Previous
Trial Profile

A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alvocidib (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary) ; Decitabine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms Zella 102
  • Sponsors Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America; Tolero Pharmaceuticals

Most Recent Events

  • 20 Oct 2022 Status changed to discontinued.
  • 21 Oct 2021 Status changed from active, no longer recruiting to completed.
  • 29 Apr 2021 Planned primary completion date changed from 1 Feb 2023 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top